{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:46:21Z","timestamp":1779169581331,"version":"3.51.4"},"reference-count":11,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>Antihypertensive drugs (AHTs) are associated with lowered risks of neurodegenerative diseases and stroke. However, the relative risks associated with different AHT classes are unclear. Using an electronic health record network with 34 million eligible patients, we compared rates of these disorders over a 2-year period, in propensity score-matched cohorts of people taking calcium channel blockers (CCBs) compared with those taking other AHT classes. CCBs were associated with a higher incidence of all disorders compared with renin-angiotensin system agents, and a higher incidence of dementia and cerebrovascular disease compared with diuretics. CCBs were associated with a lower incidence of movement disorders and cerebrovascular disease compared with beta-blockers. The data show that AHT classes confer differential risks of neurodegenerative and cerebrovascular diagnoses.<\/jats:p>","DOI":"10.1192\/bjp.2020.249","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T11:29:11Z","timestamp":1610018951000},"page":"283-285","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":6,"title":["Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes"],"prefix":"10.1192","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6719-1126","authenticated-orcid":false,"given":"Paul J.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Colbourne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sierra","family":"Luciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"S0007125020002494_ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0230-6"},{"key":"S0007125020002494_ref5","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2019.157"},{"key":"S0007125020002494_ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.13480"},{"key":"S0007125020002494_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30400-4"},{"key":"S0007125020002494_ref3","first-page":"5780809","article-title":"Risk of Parkinson's disease in the users of antihypertensive agents: an evidence from the meta-analysis of observational studies","author":"Mullapudi","year":"2016","journal-title":"J Neurodegener Dis"},{"key":"S0007125020002494_ref9","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181d61eeb"},{"key":"S0007125020002494_ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030876"},{"key":"S0007125020002494_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-015-0129-0"},{"key":"S0007125020002494_ref7","article-title":"Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA","author":"Taquet","journal-title":"Lancet Psychiatry"},{"key":"S0007125020002494_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30393-X"},{"key":"S0007125020002494_ref6","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120936501"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125020002494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T09:11:23Z","timestamp":1619601083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125020002494\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0007125020002494"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2020.249","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"Copyright \u00a9 The Authors 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}